Guangzhou Innogen Pharmaceutical Group Co Ltd Class H 2591

HKEX · Hong Kong SAR China · Health Technology

HKD 3.73-0.12 (-3.12%)

Market closed· Oct 2, 2026, 8:08 AM UTC· HKD · Data may be delayed

Company news

Yahoo FinanceAug 04, 2026

Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa

Innogen Pharmaceuticals (HK.2591), a biopharmaceutical company dedicated to innovative drug discovery and industrialization in metabolic diseases, today announced that its Efsubaglutide alfa manufacturing facility in Suzhou has officially passed a compliance inspection conducted by the Brazilian National Health Surveillance Agency (ANVISA) in accordance with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacturing Practice (GMP) standards, and has received the GMP certificate

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.